Cargando…
Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydr...
Autor principal: | Rapoport, Bernardo Leon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327850/ https://www.ncbi.nlm.nih.gov/pubmed/28260945 http://dx.doi.org/10.2147/CMAR.S97543 |
Ejemplares similares
-
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017) -
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018) -
Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015) -
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
por: Rapoport, Bernardo Leon, et al.
Publicado: (2017) -
Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
por: Hesketh, Paul J., et al.
Publicado: (2016)